JC10 Rec'd PCT/PTO 28 OCT 2005

FORM PTO-1390 (Modified)
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE
(REV 12-2004)

		ANSMITTAL LETTER TO THE UNITED STATES	ATTORNEY'S DOCKET NUMBER										
		DESIGNATED/ELECTED OFFICE (DO/EO/US)	065691-0413										
	(CONCERNING A FILING UNDER 35 U.S.C. 371	U.S. APPLIONTION NOW (INTRODUCTO, SER 3745, F. D. 16). Unassituted 2 2 5 0 0 0										
	PCT/IB	IONAL APPLICATION NO. INTERNATIONAL FILING DATE 04/28/2004	PRIORITY DATE CLAIMED 04/28/2003										
	TITLE OF INVENTION USE OF TYROSINE KINASE INHIBITORS FOR TREATING CEREBRAL ISCHEMIA												
APPLICANT(S) FOR DO/EO/US													
Jean-Pierre KINET et al. Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:													
1.													
2.		This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.											
3.		This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.											
4.		The US has been elected (Article 31).											
5.	\boxtimes	A copy of the International Application as filed (35 U.S.C. 371(c)(2))											
		is attached hereto (required only if not communicated by the International Bureau).											
ļ			•										
		is not required, as the application was filed in the United States R	eceiving Office (RO/US)										
6.		An English language translation of the International Application as filed (
		is attached hereto.											
		has been previously submitted under 35 U.S.C. 154(d)(4).	tiolo 10 (25 II S C 271(o)(3))										
7.		Amendments to the claims of the International Application under PCT Ar are attached hereto (required only if not transmitted by the International Application under PCT Ar											
	-	have been communicated by the International Bureau.											
		have not been made; however, the time limit for making such amo	endments has NOT expired.										
		have not been made and will not be made.											
8.		An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).											
9.		An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).											
10.		An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).											
1		o 20 below concern other document(s) or information included:											
	\boxtimes	An Information Disclosure Statement under 37 CFR 1.97 and 1.98.	line and 2.24 in included										
12.		An assignment document for recording. A separate cover sheet in comp	bliance with 37 CFR 3.28 and 3.31 is included.										
	\boxtimes	A Preliminary Amendment.											
	\boxtimes	An Application Data Sheet under 37 CFR 1.76.											
		A substitute specification.											
		A power of attorney and/or change of address letter. A Transmittal of Nucleotide Sequence And/Or Amino Acid Sequence Dis	closures: Statement to Support Filing and										
11.	\boxtimes	A Transmittal of Nucleotide Sequence And/Or Amino Acid Sequence Dis Submission in Accordance with 37 C.F.R. §1.821-§1.825; Paper Copy of											
		Form (CRF) Diskette.	= -4-0										
18.		A second copy of the published international application under 35 U.S.C.	154(d)(4).										
l l		A second copy of the English language translation of the international ap											
20.		Other items or information: Copy of International Search Report (2 page											
		1390 (Modified)	·										
	IVI P I U	1000 (MIDGINEU)											

JC06 Rec'd PCT/PTC 28 OCT 2003

Unassigned 555 060 PCT/IB2004/001874 06569							EY'S DOCKET NUMBER 1-0413						
File following rees have been submitted:													
	ational fee	•	\$300	\$	300.00								
22. Examin If International preti provisions of PC All other situations			\$	200.00									
23. Search	fee												
Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the													
USPTO as an In	, ,												
International Search													
All other situations	• •	•	 \$	500.00									
			\$	1000.00									
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$ for each additional 50 sheets of paper or fraction thereof.													
Total Sheets	Extra Sh			lumber of each additional 50 or fraction RATE			i						
. 0.0. 0.100.0				(round up to a whole number)		x \$250.00							
117 - 100 =	17	/50 =		1			\$	250.00					
Surcharge of \$130. claimed priority date		1.492(e)	\$	0.00									
CLAIMS			ER FILED	NUMBER EXTRA									
Total Claims		3	- 20 =	0	x \$	50.00	\$	0.00					
Independent Claim		1	- 3 =	0	+ \$	200.00 360.00	\$	0.00					
MULTIPLE DEPEN	DENT CL	AIM(S) (i	\$ \$	0.00									
TOTAL OF ABOVE CALCULATIONS =								1250.00					
Applicant claims small entity status. See 37 CFR 1.27. Fees above are \$ 625.00 reduced by 1/2.													
SUBTOTAL =								625.00					
Processing fee of 1 from the earliest cla		_	\$	0.00									
			\$	625.00									
Fee for recording th	ne enclose	d assign	\$	0.00									
accompanied by ar	appropria	ate cover	sheet (37 C	FR 3.28, 3.31). 40.00 pe									
				TOTAL	FEES EN	ICLOSED =	\$	625.00					
								Amount to be refunded:					
								charged:					
a. A chec	k in the a	mount o	f \$625.00	to cover the above fees	s is enclos	sed.			N.				
b. Please charge my Deposit Account No. 19-0741 in the amount of to cover the above fees. A duplicate copy of this sheet is enclosed.													
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any													
overpayment to Deposit Account No. 19-0741. A duplicate copy of this sheet is enclosed. d. Fees are to be charge to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.													
NOTE: Where a	n appro	priate ti	me limit u	nder 37 CFR 1.495 ha	s not be	en met, a p	etition t	o revive (37	n on P10-2038. CFR 1.137(a) or (b))			
must be filed an	a grante	d to res	store the l	nternational Applicati	on to pe	nding statu	2	en. 1	•				
SEND ALL COR	RESPON	IDENCE	TO:		SIGNATI			10/1/2/					
Foley	& Lardne	rIIP	· · · -										
1			B. Maebius										
Customer Number: 22428 NAME 35,264													
							RATION NUMBER						
1			VATION NUMBER										

10/555060 JC06 Rec'd PCT/PTO 28 OCT 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE ATTORNEY DOCKET NO. 065691-0413

Applicant:

Jean-Pierre KINET et al.

Title:

USE OF TYROSINE KINASE INHIBITORS FOR TREATING

CEREBRAL ISCHEMIA

Appl. No.:

Unassigned

Filing Date: 10/28/2005

Examiner:

Unassigned

Art Unit:

Unassigned

TRANSMITTAL OF NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

Enclosed are copies of the Sequence Listing and Statement to Support Filing and Submission in accordance with 37 C.F.R. § 1.821-§1.825. Also enclosed is a diskette containing the Sequence Listing in computer readable form.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

Stephen B. Maebius

Attorney for Applicant Registration No. 35,264

October 28, 2005

Date

FOLEY & LARDNER LLP

Customer Number: 22428

Telephone:

(202) 672-5569

Facsimile:

(202) 672-5399